Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with ...

Colorectal cancer (CRC ... This unexpected role highlights why DUSP6 is now seen as a possible target for new treatments. Our research not only explains why some colon cancers are so aggressive ...

Colorectal cancer (CRC) is a type of cancer that begins in the colon (large intestine) or rectum, which are parts of the digestive system.

The possibility of a new therapy for colorectal cancer could be achieved by blocking DUSP6, a protein that is important for ...

Machine learning and artificial intelligence (AI) techniques and analysis of large datasets have helped University of ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Machine learning and artificial intelligence (AI) techniques and analysis of large datasets have helped University of Birmingham researchers to discover proteins that have strong predictive potential ...

Colorectal cancer has become increasingly common in younger people, with one in five cases now diagnosed in patients in their early 50s or younger, according to the American Cancer Society.